Qaid Ahmed Shagera,Olivier Gheysens,Emilie Jonard,Emmanuel Seront,Renaud Lhommel,Frederic E Lecouvet,Bertrand Tombal,François Jamar
{"title":"Bone marrow scintigraphy as a prognostic marker of overall survival in mCRPC patients treated with Radium-223 dichloride.","authors":"Qaid Ahmed Shagera,Olivier Gheysens,Emilie Jonard,Emmanuel Seront,Renaud Lhommel,Frederic E Lecouvet,Bertrand Tombal,François Jamar","doi":"10.1007/s00259-025-07589-1","DOIUrl":null,"url":null,"abstract":"PURPOSE\r\nTo evaluate the potential prognostic value of pretherapeutic Bone Marrow Scintigraphy (BMS) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with Ra-223 dichloride (Ra-223).\r\n\r\nMETHODS\r\nWe analyzed 28 mCRPC patients who performed BMS and treated with Ra-223. Visual image analysis was performed and defined as follows: normal distribution (uptake in the vertebral column and bony pelvis) vs. medullary expansion (uptake at the distal half of femoral and/or humeral diaphysis or more distally). Correlation between medullary expansion status and baseline laboratory factors was performed. Survival analyses for evaluating the association between medullary expansion and other variables with overall survival (OS) were conducted using cox regression hazard model and Kaplan Meier methods.\r\n\r\nRESULTS\r\nA total of 130 doses of Ra-223 were administered, with 17 (60%) patients received 6 cycles. BMS status was significantly correlated with hemoglobin levels (p < 0.001), PSA levels (p = 0.008), the number of prior systemic therapies (p = 0.032) and radiotherapy (p = 0.01). Median OS was 19 months, with 16 patients dead. Among variables tested, BMS status, hemoglobin, number of therapies, and number of Ra-223 cycles were significantly associated with OS (hazard ratios: 3.3, p = 0.02; 0.75, p = 0.042; 1.74, p = 0.019; 4.6, p = 0.006; respectively). Patients with normal BMS had a median OS of 33 months vs. 7.6 months in those with medullary expansion (log-rank 5.5, p = 0.019).\r\n\r\nCONCLUSION\r\nThis study demonstrated a significant association between medullary expansion status on BMS and OS in mCRPC patients treated with Ra-223. Patients exhibiting medullary expansion have worse outcomes compared to those without expansion. Medullary expansion was correlated with adverse prognostic biomarkers commonly linked to worse outcomes in mCRPC.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"28 1","pages":""},"PeriodicalIF":7.6000,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Nuclear Medicine and Molecular Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00259-025-07589-1","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
PURPOSE
To evaluate the potential prognostic value of pretherapeutic Bone Marrow Scintigraphy (BMS) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with Ra-223 dichloride (Ra-223).
METHODS
We analyzed 28 mCRPC patients who performed BMS and treated with Ra-223. Visual image analysis was performed and defined as follows: normal distribution (uptake in the vertebral column and bony pelvis) vs. medullary expansion (uptake at the distal half of femoral and/or humeral diaphysis or more distally). Correlation between medullary expansion status and baseline laboratory factors was performed. Survival analyses for evaluating the association between medullary expansion and other variables with overall survival (OS) were conducted using cox regression hazard model and Kaplan Meier methods.
RESULTS
A total of 130 doses of Ra-223 were administered, with 17 (60%) patients received 6 cycles. BMS status was significantly correlated with hemoglobin levels (p < 0.001), PSA levels (p = 0.008), the number of prior systemic therapies (p = 0.032) and radiotherapy (p = 0.01). Median OS was 19 months, with 16 patients dead. Among variables tested, BMS status, hemoglobin, number of therapies, and number of Ra-223 cycles were significantly associated with OS (hazard ratios: 3.3, p = 0.02; 0.75, p = 0.042; 1.74, p = 0.019; 4.6, p = 0.006; respectively). Patients with normal BMS had a median OS of 33 months vs. 7.6 months in those with medullary expansion (log-rank 5.5, p = 0.019).
CONCLUSION
This study demonstrated a significant association between medullary expansion status on BMS and OS in mCRPC patients treated with Ra-223. Patients exhibiting medullary expansion have worse outcomes compared to those without expansion. Medullary expansion was correlated with adverse prognostic biomarkers commonly linked to worse outcomes in mCRPC.
期刊介绍:
The European Journal of Nuclear Medicine and Molecular Imaging serves as a platform for the exchange of clinical and scientific information within nuclear medicine and related professions. It welcomes international submissions from professionals involved in the functional, metabolic, and molecular investigation of diseases. The journal's coverage spans physics, dosimetry, radiation biology, radiochemistry, and pharmacy, providing high-quality peer review by experts in the field. Known for highly cited and downloaded articles, it ensures global visibility for research work and is part of the EJNMMI journal family.